A new peer-reviewed study highlights a potential breakthrough in early disease detection, as California-based biotech firm EarlyDiagnostics reports strong validation results for its blood-based diagnostic platform. The findings, published in a leading U.S. scientific journal, suggest the technology could help streamline screening for multiple serious conditions using a single blood draw.
Study Validates Multi-Disease Detection Technology
EarlyDiagnostics, Inc. announced that its proprietary MethylScan™ platform has been validated in a study published in Proceedings of the National Academy of Sciences (PNAS). The research demonstrates the platform’s ability to detect multiple cancers, liver diseases, and organ abnormalities from a single blood sample.
The study analyzed 1,061 patient samples, showing strong performance across several key areas:
- Multi-cancer detection
- Liver disease classification
- Tissue-of-origin identification
Unlike traditional screening methods that often require separate tests or extensive sequencing, the MethylScan platform uses methylation-based enrichment. This approach reduces sequencing demands, potentially lowering costs and making large-scale screening more feasible in U.S. healthcare settings.
Leadership Emphasizes Accessibility and Early Detection
“This publication validates the scientific foundation of our platform and supports our vision of a single, affordable blood test for early disease detection,” said Jasmine Zhou, co-founder and CEO of EarlyDiagnostics.
Zhou added that the company is focused on expanding clinical validation and forming strategic partnerships to bring the technology into broader use across hospitals and diagnostic networks.
Additional Clinical Validation Strengthens Findings
Beyond the PNAS study, independent validation has also been conducted through a multi-site, blinded clinical trial presented at The Liver Meeting 2025, one of the largest hepatology conferences in the United States.
In that study, Neehar Parikh of the University of Michigan evaluated the MethylScan platform in combination with alpha-fetoprotein (AFP), a commonly used biomarker. The results demonstrated effectiveness in detecting hepatocellular carcinoma (HCC), the most common type of liver cancer.
Because the trial was independently led and blinded, it provides real-world clinical evidence—an important step toward adoption in U.S. healthcare systems where regulatory and payer scrutiny is high.
Regulatory Progress and Expansion Plans
EarlyDiagnostics is currently operating a CLIA-certified laboratory in the United States, a requirement for clinical testing services. The company has also secured key reimbursement infrastructure, including:
- A Proprietary Laboratory Analyses (PLA) code
- Pricing determination from the Centers for Medicare & Medicaid Services (CMS)
These milestones are critical for integrating new diagnostic tools into routine clinical practice and ensuring coverage by insurers.
The company is also advancing additional validation programs targeting early detection of lung and ovarian cancers—two conditions where early diagnosis significantly improves survival rates but remains challenging with current screening methods.
Toward Broader Adoption of Liquid Biopsy Testing
Liquid biopsy technologies, which analyze biomarkers in blood rather than tissue samples, are gaining traction across the U.S. as a less invasive and potentially more scalable approach to disease detection. EarlyDiagnostics’ platform combines DNA methylation analysis with machine learning to identify disease signals across multiple conditions simultaneously.
With growing clinical evidence, peer-reviewed validation, and a focus on cost efficiency, the company is positioning its technology as a practical tool for earlier and more accessible disease detection.
Conclusion
The latest findings add to a growing body of evidence supporting multi-disease blood testing as a viable future for early diagnosis. While further validation and regulatory steps remain, EarlyDiagnostics’ MethylScan platform could play a significant role in reshaping how diseases like cancer and liver conditions are detected and managed across the United States healthcare system.
“Beer practitioner. Pop culture maven. Problem solver. Proud social media geek. Total coffee enthusiast. Hipster-friendly tv fan. Creator.”
